Table 4 The participants and specimens included in this study

1

Detection limit

2

one serum sample and one neutralizing antibody from two convalescent patients, respectively;

0

–

2

Comparison between UPT-POCT and ELISA

39

39 samples,

from 27 patients at acute phase (7–10 days)

0

–

3

Definition of cutoff of UPT-POCT for detecting serum sample

210

140 samples,

from 140 COVID-19 patients at different courses

70 samples,

from 70 healthy people

–

4

Diagnostic performance of UPT-POCT in the hospital settings

782

387 samples, from 387 COVID-19 patients’ samples at different courses

395 samples,

from 395 healthy people

–

5

The relationship between RBD-specific total antibodies and neutralizing activity

812

528, from recovered or recurrent patients*

284

≥ 14

UPT-POCT for predicting the protective effects in COVID-19 patients

312

312 serum samples from 213 recovered and 99 PCR re-positive COVID-19 patients*

0

≥ 8

6

UPT-POCT for predicting the protective effects in vaccinated individuals

35

35 vaccinated individuals with NAb titers equal or higher than1:32

0

≥ 5 (except the titer 1:32)